Late MRD response determines relapse risk overall and in subsets of childhood T-cell ALL

• Verfasst von: Schrappe, Martin [VerfasserIn]
• Verfasst von: Valsecchi, Maria Grazia [VerfasserIn]
• Verfasst von: Bartram, Claus R. [VerfasserIn]
• Verfasst von: Schrauder, André [VerfasserIn]
• Verfasst von: Panzer-Grümayer, Renate [VerfasserIn]
• Verfasst von: Möricke, Anja [VerfasserIn]
• Verfasst von: Parasole, Rosanna [VerfasserIn]
• Verfasst von: Zimmermann, Martin [VerfasserIn]
• Verfasst von: Dworzak, Michael [VerfasserIn]
• Verfasst von: Buldini, Barbara [VerfasserIn]
• Verfasst von: Reiter, Alfred [VerfasserIn]
• Verfasst von: Basso, Giuseppe [VerfasserIn]
• Verfasst von: Klingebiel, Thomas [VerfasserIn]
• Verfasst von: Messina, Chiara [VerfasserIn]
• Verfasst von: Ratei, Richard [VerfasserIn]
• Verfasst von: Cazzaniga, Giovanni [VerfasserIn]
• Verfasst von: Köhler, Rolf [VerfasserIn]
• Verfasst von: Locatelli, Franco [VerfasserIn]
• Verfasst von: Schäfer, Beat W. [VerfasserIn]
• Verfasst von: Aricò, Maurizio [VerfasserIn]
• Verfasst von: Welte, Karl [VerfasserIn]
• Verfasst von: van Dongen, Jacques J.M. [VerfasserIn]
• Verfasst von: Gadner, Helmut [VerfasserIn]
• Verfasst von: Biondi, Andrea [VerfasserIn]
• Verfasst von: Conter, Valentino [VerfasserIn]
• Titel: Late MRD response determines relapse risk overall and in subsets of childhood T-cell ALL
• Titelzusatz: results of the AIEOP-BFM-ALL 2000 study
• Verf.angabe: Martin Schrappe, Maria Grazia Valsecchi, Claus R. Bartram, André Schrauder, Renate Panzer-Grümayer, Anja Möricke, Rosanna Parasole, Martin Zimmermann, Michael Dworzak, Barbara Buldini, Alfred Reiter, Giuseppe Basso, Thomas Klingebiel, Chiara Messina, Richard Ratei, Giovanni Cazzaniga, Rolf Koehler, Franco Locatelli, Beat W. Schäfer, Maurizio Aricò, Karl Welte, Jacques J.M. van Dongen, Helmut Gadner, Andrea Biondi, and Valentino Conter
• E-Jahr: 2011
• Jahr: August 25 2011
• Umfang: 8 S.
• Illustrationen: Diagramme
• Fussnoten: Gesehen am 26.10.2022
• Titel Quelle: Enthalten in: Blood
• Ort Quelle: Washington, DC : American Society of Hematology, 1946
• Jahr Quelle: 2011
• Band/Heft Quelle: 118(2011), 8 vom: Aug., Seite 2077-2084
• ISSN Quelle: 1528-0020
• DOI: doi:10.1182/blood-2011-03-338707
• Datenträger: Online-Ressource
• Sprache: eng
• K10plus-PPN: 1820032663

Abstract

The prognostic value of MRD in large series of childhood T-ALL has not yet been established. Trial AIEOP-BFM-ALL 2000 introduced standardized quantitative assessment of MRD for stratification, based on immunoglobulin and TCR gene rearrangements as polymerase chain reaction targets: Patients were considered MRD standard risk (MRD-SR) if MRD was negative at day 33 (time point 1 [TP1]) and day 78 (TP2), analyzed by at least 2 sensitive markers; MRD intermediate risk (MRD-IR) if positive either at day 33 or 78 and < 10−3 at day 78; and MRD high risk (MRD-HR) if ≥ 10−3 at day 78. A total of 464 patients with T-ALL were stratified by MRD: 16% of them were MRD-SR, 63% MRD-IR, and 21% MRD-HR. Their 7-year event-free-survival (SE) was 91.1% (3.5%), 80.6% (2.3%), and 49.8% (5.1%) (P < .001), respectively. Negativity of MRD at TP1 was the most favorable prognostic factor. An excellent outcome was also obtained in 32% of patients turning MRD negative only at TP2, indicating that early (TP1) MRD levels were irrelevant if MRD at TP2 was negative (48% of all patients). MRD ≥ 10−3 at TP2 constitutes the most important predictive factor for relapse in childhood T-ALL. The study is registered at http://www.clinicaltrials.gov; “Combination Chemotherapy Based on Risk of Relapse in Treating Young Patients With Acute Lymphoblastic Leukemia,” protocol identification #NCT00430118 for BFM and #NCT00613457 for AIEOP.